Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. 
 
The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.

Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Biotechnology

Life Sciences

Therapeutics

Resalis Therapeutics

Alessandro Toniolo

Luca Borgio

Pietro Puglisi

Michael Hodges

Antonio Leone

Sakari Kauppinen

Almut Nitsche

Barbara Domizzi

Claus Andersson

Riccardo Panella

Resalis Therapeutics

Org chart

Similar companies